MRD tests provide real-time molecular insights for patient response to therapy, differentiating responders from non-responders. Follow response to investigational therapies prospectively in real-time, or retrospectively analyze samples in order to gain deeper insights into the trajectory of response to an investigational therapy.
*image adapted from van Dorp J et al. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. Nat Med. 2023 Mar;29(3):588-592. doi: 10.1038/s41591-022-02199-y. Epub 2023 Feb 2. Erratum in: Nat Med. 2024 Jan;30(1):304.